Sequence: WEAKLAKALAKALAKHLAKALAKALKA
| Experiment Id | EXP000864 |
|---|---|
| Paper | Development of a lipoplex-type mRNA carrier composed of an ionizable lipid with a vitamin E scaffold |
| Peptide | KALA |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | no |
| Label Confidence | medium |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | |
| Mixing Ratio | |
| Formulation Format | lipoplex (ionizable lipid LNP + CPP + mRNA) |
| Formulation Components | Main lipid EPC; DOPE; cholesterol (3:4:3 molar). Surface peptide STR-KALA. |
| Size Nm | 115.00 |
| Zeta Mv | 27.00 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | murine bone marrow-derived dendritic cells (BMDCs, primary) |
| Animal Model | |
| Administration Route | |
| Output Type | MHC-I antigen presentation (B3Z assay absorbance 595 nm) |
| Output Value | ~0.05 absorbance units |
| Output Units | |
| Output Notes | BMDCs transfected with OVA-mRNA lipoplex (0.4 µg nucleic acid / 1×10^6 cells); co-cultured with B3Z reporter cells; β-gal absorbance used as presentation index (Fig. 7). |
| Toxicity Notes | |
| Curation Notes |